Merck, Inc.
🇵🇭Philippines
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Intron A (interferon alfa-2b; SCH 30500)
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 299
- Registration Number
- NCT00723710
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
Withdrawn
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00724672
Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00724243
Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)Drug: Rebetol (ribavirin)
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 332
- Registration Number
- NCT00724464
PegIntron Injection Surveillance Plan (Study P04123)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1267
- Registration Number
- NCT00723931
Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)
Completed
- Conditions
- Inflammatory Bowel DiseaseCrohn's Disease
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 245
- Registration Number
- NCT00723840
Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)
Terminated
- Conditions
- Hepatitis C, ChronicHepacivirus
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)Drug: Ribavirin (SCH 18908)Behavioral: Patient assistance program
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT00723879
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Completed
- Conditions
- Hepatitis C, ChronicHepacivirus
- Interventions
- Biological: Peginterferon alfa-2b (PegIntron)Drug: Rebetol (Ribavirin)Behavioral: Psychotherapy support program
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT00723892
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 279
- Registration Number
- NCT00723645
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
Completed
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 505
- Registration Number
- NCT00724230
© Copyright 2025. All Rights Reserved by MedPath